Goal 2: Reduce Human Disease

To extend our knowledge of the pathobiology of heart, lung, blood, and sleep disorders and enable clinical investigations that advance the prediction, prevention, preemption, treatment, and cures of human disease.

Goal 2: Reduce Human Disease

Submitted by (@jlaakso)

Chronic stress and cardiovascular/metabolic disease

Chronic stress is a risk factor for obesity, cardiovascular disease, atherosclerosis, and stroke. Glucocorticoid hormones are elevated chronically in stressed conditions and are thought to contribute to the pathogenesis of metabolic and cardiovascular disease. Despite strong evidence for this, non-pharmacologic therapies to reduce stress are not currently part of standard care for the prevention or treatment of metabolic ...more »

Voting

11 net votes
12 up votes
1 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@hongw0)

International collaboration for genetic and metabolic research on specific human population

During recent years, clinical research including well-organized randomized clinical trials in developed countries generated large database and human biological sample banks. These are valuable resources for human disease research. Mechanisms to encourage and facilitate international collaboration for genetic and metabolic research using database and human biological samples from specific human disease population of international ...more »

Voting

4 net votes
4 up votes
0 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@amtager)

Fibrosis Across Organs: Bringing Together Investigators of Fibrosis of the Heart, Lungs and Bone Marrow

Fibrosis can affect essentially any tissue or organ, including the heart, lungs and bone marrow. Effective anti-fibrotic therapy has long been elusive, and transplantation has been the only therapy capable of restoring patient function as fibrotic diseases progress to organ failure. Although these diseases present clinically with organ-specific manifestations, they are now thought to share many common pathogenetic mechanisms. ...more »

Voting

16 net votes
20 up votes
4 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@nhlbiforumadministrator)

Clinical trial of AAT augmentation therapy in PI MZ subjects

Although severely alpha-1 antitrypsin deficiency (PI ZZ) individuals are rare, PI MZ subjects comprise approximately 3% of the US population. Mounting evidence suggests that PI MZ is a significant risk factor for COPD. A clinical trial of COPD exacerbation frequency using AAT augmentation therapy in PI MZ subjects with moderate-to-severe COPD could provide a rationale for AAT augmentation therapy (or small molecule neutrophil ...more »

Voting

1 net vote
1 up votes
0 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@sdas00)

Role of extracellular RNAs in cardiac biology and disease

Extracellular RNAs including miRNAs, piRNAs, tRNA fragments and long non-coding RNA fragments have been found in plasma and correlated with disease. For microRNAs, there is emerging evidence of a functional role for these extracellular RNAs in cardiovascular diseases. However, there needs to be a concerted effort to: 1) develop new models and tools to study the role of these entities; 2) validate findings from different ...more »

Voting

-7 net votes
4 up votes
11 down votes
Active